PMID- 19843084
OWN - NLM
STAT- MEDLINE
DCOM- 20101116
LR  - 20131121
IS  - 1365-2230 (Electronic)
IS  - 0307-6938 (Linking)
VI  - 35
IP  - 4
DP  - 2010 Jun
TI  - A randomized double-blind controlled trial to compare a triclosan-containing 
      emollient with vehicle for the treatment of atopic dermatitis.
PG  - e109-12
LID - 10.1111/j.1365-2230.2009.03719.x [doi]
AB  - The use of topical antiseptics in the treatment of atopic dermatitis (AD) has 
      previously been explored. However, no triclosan-containing leave-on emollient has 
      been evaluated previously, to our knowledge. The aims of this study were to 
      assess the safety and efficacy of an emollient containing triclosan compared with 
      the emollient alone (vehicle) for the treatment of AD. Eligible patients with 
      mild to moderate AD were randomized to receive either the study cream or vehicle. 
      All patients also received a low-potency corticosteroid cream to use during the 
      treatment phase of the study if necessary. Patients were assessed for severity 
      according to the SCORing Atopic Dermatitis (SCORAD) Index, amount of 
      corticosteroid used, patient assessment of cream, and adverse events (AEs). In 
      total, 60 patients received either the study cream or vehicle, and an 
      intention-to-treat analysis was performed. At day 14, there was a significant 
      decrease in SCORAD from baseline for the study cream compared with vehicle (P < 
      0.05). At day 27, although there was an improved mean reduction from baseline, 
      this was no longer significant (P > 0.05). Only four patients had mild 
      treatment-related AEs. The mean total amount of topical steroid applied by the 
      patients using the study was significantly lower than that used by controls (P = 
      0.40). Triclosan-containing leave-on emollient was safe and highly acceptable to 
      patients. However, the overall benefit on day 27 was not significant. 
      Nevertheless, the amount of topical steroid used by patients was significantly 
      less with the study cream than with the vehicle, thus further studies are needed 
      to confirm its steroid-sparing effect.
FAU - Tan, W P
AU  - Tan WP
AD  - National Skin Centre, Singapore City, Singapore. wptan@nsc.gov.sg
FAU - Suresh, S
AU  - Suresh S
FAU - Tey, H L
AU  - Tey HL
FAU - Chiam, L Y
AU  - Chiam LY
FAU - Goon, A T
AU  - Goon AT
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20091019
PL  - England
TA  - Clin Exp Dermatol
JT  - Clinical and experimental dermatology
JID - 7606847
RN  - 0 (Anti-Infective Agents, Local)
RN  - 0 (Emollients)
RN  - 0 (Glucocorticoids)
RN  - 4NM5039Y5X (Triclosan)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Anti-Infective Agents, Local/adverse effects/*therapeutic use
MH  - Child
MH  - Dermatitis, Atopic/*drug therapy
MH  - Double-Blind Method
MH  - Drug Therapy, Combination
MH  - Emollients/adverse effects/*therapeutic use
MH  - Female
MH  - Glucocorticoids/therapeutic use
MH  - Humans
MH  - Male
MH  - Severity of Illness Index
MH  - Treatment Outcome
MH  - Triclosan/adverse effects/*therapeutic use
MH  - Young Adult
EDAT- 2009/10/22 06:00
MHDA- 2010/11/17 06:00
CRDT- 2009/10/22 06:00
PHST- 2009/10/22 06:00 [entrez]
PHST- 2009/10/22 06:00 [pubmed]
PHST- 2010/11/17 06:00 [medline]
AID - CED3719 [pii]
AID - 10.1111/j.1365-2230.2009.03719.x [doi]
PST - ppublish
SO  - Clin Exp Dermatol. 2010 Jun;35(4):e109-12. doi: 10.1111/j.1365-2230.2009.03719.x. 
      Epub 2009 Oct 19.